BCYC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Bicycle Therapeutics PLC (BCYC) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows bearish technical indicators, insider selling, and no recent positive news or strong catalysts. While the company has shown significant revenue growth, its financials still reflect losses, and analysts remain cautious about its near-term potential. Given the lack of strong proprietary trading signals and the overall sentiment, holding off on buying is recommended.
The technical indicators for BCYC are bearish. The MACD histogram is negative and contracting, the RSI is neutral at 26.421, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot point of 5.86, with support at 5.314 and resistance at 6.407.
Revenue increased significantly by 338.49% YoY in Q3 2025, showing strong growth potential. Gross margin remains at 100%.
Insiders are selling heavily, with a 253.11% increase in selling activity over the last month. Analysts have a cautious outlook, with a Hold rating and uncertainty around the company's key drug pipeline. No recent news or event-driven catalysts. The stock trend analysis predicts further potential declines in the short term.
In Q3 2025, revenue increased by 338.49% YoY to $11.73 million. However, the company remains unprofitable, with a net income of -$59.1 million (an improvement of 16.33% YoY) and an EPS of -0.85 (up 14.86% YoY).
Truist initiated coverage with a Hold rating and a $10 price target. Analysts highlight uncertainty around the company's key drug pipeline and its market potential, with other programs still in early development stages.
